Mupadolimab: A B Cell Activating Anti-CD73 Antibody for Immunotherapy of Cancer & Viral Diseases

Time: 2:15 pm
day: Day Two


• Highlighting that Mupadolimab is a humanized anti CD73 antibody that activates B cells leading to expression of CD69, trafficking to lymph nodes and differentiation into antigen specific plasma cells and memory B cells

• Demonstrating how the antibody has shown preliminary evidence of anti-tumor activity both as monotherapy and in combination with anti-PD1 in patients with nonsmall cell lung cancer and head and neck cancers

• Understanding how treatment of patients with COVID 19 with Mupadolimab has led to sustained high titers of antiviral antibodies

• Discussing the mechanism of action of Mupadolimab and its use in ongoing cancer clinical trials